Trial
NCT03654729
Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Egetis Therapeutics
Collaborators
Solasia Pharma K.K.
Condition
Colorectal Cancer
Intervention
Calmangafodipir (2 µmol/kg)
Why stopped
On 23 January 2020, the Sponsor announced that the United States (US) Food and Drug Administration (FDA) had issued a clinical hold in the US of the POLAR program.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-12-17